Von Willebrand Disease (VWD) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Von Willebrand Disease Emerging Therapy and TPP Insights

Thelansis's "Von Willebrand Disease (VWD) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Von Willebrand Disease Overview

Von Willebrand disease is an inherited bleeding disorder caused by quantitative deficiency or qualitative dysfunction of von Willebrand factor, impairing platelet adhesion and, in some patients, factor VIII stability. Clinical severity varies widely, ranging from mild mucosal bleeding to severe recurrent hemorrhage. Current treatment includes desmopressin in responsive patients, VWF-containing concentrates, antifibrinolytic therapy, and prophylaxis for selected patients with severe or frequent bleeding. The therapeutic landscape has already advanced beyond episodic plasma-derived replacement: recombinant VWF vonicog alfa is FDA-approved for routine prophylaxis in adults with all VWD types, following a 2025 indication expansion, while Wilate received a further FDA expansion in 2026 to include routine prophylaxis in children younger than 6 years. These advances are shifting development toward reducing treatment frequency and infusion burden while maintaining sustained hemostatic protection. Emerging approaches include agents that prolong VWF exposure, such as HMB-002, targeted therapies such as rondoraptivon pegol for selected type 2B disease, and hemostatic rebalancing strategies such as VGA039. These approaches remain investigational, but they broaden the field beyond direct VWF replacement. For stakeholders, VWD represents a high-value rare-hematology opportunity where the next advances are likely to combine longer duration, less burdensome administration, and mechanism-specific hemostatic control.

Key Highlights

• In Spain, diagnosed VWD cases are projected to increase from 708 in 2026 to 789 by 2036.
• Von Willebrand Disease (VWD) is a common inherited bleeding disorder caused by deficient or defective von Willebrand factor.
• Bleeding episodes and disease severity vary widely across patients.
• Significant unmet need remains for therapies providing effective and sustained bleeding control.

Market Overview

• The Spain VWD market is projected to grow from $55M in 2026 to $95M by 2036.
• Market growth is driven by:
• Increasing adoption of factor replacement and targeted therapies
• Improved diagnosis and disease management
• Future growth will depend on therapies offering durable bleeding prevention and improved patient outcomes.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Hoffmann-La Roche
• Vega Therapeutics, Inc.
• Octapharma
• Takeda
• Hemab ApS
• Shanghai RAAS Blood Products Co., Ltd.
• Bioverativ, a Sanofi company
• Alnylam Pharmaceuticals